FDA Clears First CELMoD Therapy for Relapsed Myeloma

The FDA has granted accelerated approval to iberdomide (Zenbexus), the first cereblon E3 ligase modulation, or CELMoD, therapy for adults with relapsed or refractory multiple myeloma. The oral drug is approved as part of a three-drug regimen with daratumumab and hyaluronidase (Darzalex Faspro) and dexamethasone.

The approval covers patients who have already received at least one line of therapy that included a proteasome inhibitor and an immunomodulatory drug. It is based on the phase III EXCALIBER-RRMM trial, in which the iberdomide combination produced a minimal residual disease-negative complete response rate of 41%, compared with 21% for daratumumab-hyaluronidase plus bortezomib and dexamethasone, a statistically significant difference.

The trial excluded patients whose disease was refractory to prior anti-CD38 therapy or bortezomib. Safety labeling includes a boxed warning for embryo-fetal toxicity requiring a risk evaluation and mitigation strategy program, as well as warnings for serious venous and arterial blood clots. Additional flagged risks include neutropenia, infections and secondary primary malignancies; common adverse events ranged from upper respiratory tract infections and fatigue to pneumonia, diarrhea, motor dysfunction, rash, sleep disorders, hypogammaglobulinemia, COVID-19 and constipation.

Bristol Myers Squibb is positioning the approval as a potential new treatment foundation in multiple myeloma, with investigator Sagar Lonial of Emory University's Winship Cancer Institute calling it a meaningful difference for patients. Because the approval is accelerated, the company will still need to provide confirmatory evidence.

Advertisement

What the EXCALIBER-RRMM Data Do and Don't Prove

Why the CELMoD Class Is a Distinct Step

Iberdomide is the first approved drug in the CELMoD class, which builds on immunomodulatory drugs that have long been central to multiple myeloma treatment. The approval gives oncologists an oral myeloma agent designed to be used in a familiar triplet structure with an anti-CD38 antibody and dexamethasone, which may make it easier to integrate into existing treatment workflows than a more complex regimen.

The 41% vs 21% Result Is Strong but Narrow

The MRD-negative complete response advantage in EXCALIBER-RRMM is compelling, but the trial's exclusions matter. Patients whose disease was refractory to prior anti-CD38 therapy or bortezomib were not studied, so the labeled population excludes a substantial group of relapsed or refractory patients. MRD-negative complete response is also a surrogate marker; accelerated approval means the FDA has accepted it as reasonably likely to predict clinical benefit, while requiring further confirmation.

Bristol Myers Squibb's Myeloma Franchise Gets a New Oral Backbone

For Bristol Myers Squibb, the decision extends its multiple myeloma portfolio with a first-in-class therapy and reinforces the company's move toward oral regimens that can be delivered in community oncology practices. The commercial upside is real, but adoption will depend on how clinicians weigh the safety burden, including the embryo-fetal toxicity REMS, clotting risk and infection risk, against the demonstrated response advantage.

Next Steps for Clinicians, Health Systems and Bristol Myers Squibb

For clinicians, health systems and the drugmaker, the decision creates specific near-term tasks.

  • Prescribers should treat the label population as the studied population: patients refractory to anti-CD38 therapy or bortezomib were excluded from EXCALIBER-RRMM, so evidence in those groups is not yet established.
  • Clinics will need to prepare for the REMS and boxed-warning requirements around embryo-fetal toxicity and serious venous/arterial thromboembolism before implementing the regimen.
  • Bristol Myers Squibb must deliver confirmatory data to convert the accelerated approval; expect regulatory scrutiny of longer-term efficacy and safety as that evidence emerges.
  • Health systems and payers should evaluate the new triplet against the daratumumab-bortezomib-dexamethasone comparator, using the 41% versus 21% MRD-negative complete response result in the studied population as the key benchmark.
  • Eligible patients with relapsed or refractory multiple myeloma can ask their care team whether their prior treatment history, including anti-CD38 or bortezomib exposure, matches the population studied in EXCALIBER-RRMM.

Risk & Opportunity Assessment

Commercial RiskMediumAccelerated approval and the need for confirmatory data create uncertainty; the regimen's label is limited by trial exclusions, but Bristol Myers Squibb has an established myeloma franchise to support launch.
Competitive RiskMediumThe regimen competes with an existing daratumumab-bortezomib-dexamethasone backbone and other multiple myeloma options; the trial did not evaluate patients refractory to CD38 or bortezomib, limiting initial competitive claims in those segments.
Regulatory RiskMediumIberdomide carries a boxed warning for embryo-fetal toxicity with a REMS, plus serious thromboembolism warnings; accelerated approval requires confirmatory evidence that could alter the risk-benefit assessment.
Reputation RiskMediumThe safety label includes embryo-fetal toxicity, blood clots, neutropenia, infections and secondary primary malignancies, which could temper physician and patient enthusiasm despite the response data.
Technology DisruptionMediumFirst-in-class CELMoD mechanism could shift the multiple myeloma treatment architecture, but it enters an already innovative field and is initially studied in a narrower population.
Commercial OpportunityHighA first approved CELMoD gives Bristol Myers Squibb a new oral triplet foundation in multiple myeloma; a 41% versus 21% MRD-negative complete response advantage is a strong launch narrative.